Form 8-K - Current report:
SEC Accession No. 0001493152-22-017162
Filing Date
2022-06-17
Accepted
2022-06-17 16:15:29
Documents
14
Period of Report
2022-06-16
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 55275
2 ex10-1.htm EX-10.1 481232
3 ex10-2.htm EX-10.2 537197
  Complete submission text file 0001493152-22-017162.txt   1426349

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lctx-20220616.xsd EX-101.SCH 2968
5 XBRL LABEL FILE lctx-20220616_lab.xml EX-101.LAB 34916
6 XBRL PRESENTATION FILE lctx-20220616_pre.xml EX-101.PRE 22795
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3768
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 221024022
SIC: 2836 Biological Products, (No Diagnostic Substances)